Abivax Provides 2026 Corporate Outlook New market insights indicate significant future expansion of the ulcerative colitis (UC) market, with obefazimod well positioned to become a future market leader in the IBD space ABTECT Phase 3 Data Safety Monitoring Board (DSMB) meeting on December 18, 2025, found no new safety signals with over 80% of participants having completed the 44-week double blind maintenance trial ABTECT-UC Phase 3 maintenance topline results expected late Q2 2026, with a subsequent US regulatory filing planned for late 2026 ENHANCE-CD Phase 2b induction trial of obefazimod in moderate-to-severely active Crohn's disease (CD) ongoing; induction results expected late 2026 22 abstracts accepted for upcoming February 2026 European Crohn's and Colitis Organization (ECCO) conference including oral presentation of obefazimod impact on fibrosis in in-vitro and preclinical models Cash runway expected into Q4 2027, after full debt reimbursement in Q4 2025 PARIS, France – January 7, 2026 – 10:05 PM CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced its 2026 corporate outlook, highlighting new market insights, progress in the ABTECT-UC and ENHANCE-CD trials, and advances in its therapeutic pipeline. Updates from the ABTECT Phase 3 maintenance trial evaluating obefazimod for the treatment of moderate-to-severely active UC reinforce the therapy's safety profile and inform potential future combination strategies.
